CRM Stock Analysis: Salesforce.com | NYSE
Software - Application | NYSE, USA | Market Cap: 207.437m USD | 12M Return: 1.4% | US79466L3024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.51B
EPS Trend: 97.7%
Qual. Beats: 5
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Salesforce, Inc. is a global provider of customer relationship management (CRM) technology services, operating across the United States, Europe, and the Asia Pacific. The company offers a broad enterprise software portfolio spanning AI-powered agent platforms (Agentforce), data management (Data 360, Informatica), workplace collaboration (Slack), marketing, commerce, integration and analytics tools, and field service solutions, including a packaged suite for small and medium-sized businesses (Salesforce Starter).
The company serves a diverse set of end markets, including financial services, healthcare and life sciences, manufacturing, automotive, and government. Salesforce is classified within the Information Technology sector and the Application Software sub-industry, a segment dominated by cloud-based, subscription-priced SaaS business models that monetize through recurring per-user or consumption-based fees rather than one-time license sales.
Founded in 1999 and headquartered in San Francisco, California, Salesforce has been publicly traded on the NYSE under the ticker CRM since its June 2004 IPO, and is currently one of the largest constituents of the application software space by market capitalization.
- Agentforce AI agent adoption accelerates enterprise subscription revenue growth
- Operating margin expansion from cost discipline and AI efficiency gains
- Remaining performance obligations growth signals strong future revenue pipeline
- Competition intensifies from Microsoft Copilot and ServiceNow in enterprise AI agents
| Net Income: 9.66b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 1.02 > 1.0 |
| NWC/Revenue: -9.68% < 20% (prev 7.09%; Δ -16.77% < -1%) |
| CFO/TA 0.14 > 3% & CFO 15.8b > Net Income 9.66b |
| Net Debt (2.17b) to EBITDA (13.0b): 0.17 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (821.0m) vs 12m ago -14.66% < -2% |
| Gross Margin: 77.28% > 18% (prev 77.65%; Δ -0.37% > 0.5%) |
| Asset Turnover: 42.41% > 50% (prev 40.48%; Δ 1.93% > 0%) |
| Interest Coverage Ratio: 29.00 > 6 (EBIT TTM 9.40b / Interest Expense TTM 324.0m) |
| A: -0.04 (Total Current Assets 22.1b - Total Current Liabilities 26.3b) / Total Assets 110b |
| B: 0.25 (Retained Earnings 27.1b / Total Assets 110b) |
| C: 0.09 (EBIT TTM 9.40b / Avg Total Assets 104b) |
| D: 0.54 (Book Value of Equity 38.4b / Total Liabilities 71.2b) |
| Altman-Z'' = 1.73 = BBB |
| DSRI: 1.02 (Receivables 6.32b/5.60b, Revenue 43.9b/39.5b) |
| GMI: 1.00 (GM 77.65% / 77.28%) |
| AQI: 1.10 (AQ_t 0.75 / AQ_t-1 0.69) |
| SGI: 1.11 (Revenue 43.9b / 39.5b) |
| TATA: -0.06 (NI 9.66b - CFO 15.8b) / TA 110b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of August 30, 2026, the stock is trading at USD 256.00 with a total of 34,320,234 shares traded. Over the past week, the price has changed by +22.39%, over one month by +41.05%, over three months by +45.69% and over the past year by +1.43%.
Current recommended Stop Loss: 242.90 (which is 5.1% or 1.2 ATR below the current price).
Salesforce.com has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy CRM.
- StrongBuy: 28
- Buy: 13
- Hold: 12
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 244 | -4.7% |
P/E Trailing = 23.0815
P/E Forward = 15.1057
P/S = 4.8434
P/B = 4.388
P/EG = 0.8536
Revenue TTM = 43.9b USD
EBIT TTM = 9.40b USD
EBITDA TTM = 13.0b USD
Long Term Debt = 10.4b USD (from longTermDebt, last fiscal year)
Short Term Debt = 531.0m USD (from shortTermDebt, last quarter)
Debt = 13.6b USD (corrected: LT Debt 10.4b + ST Debt 531.0m) + Leases 2.60b
Net Debt = 2.17b USD (calculated: Debt 13.6b - CCE 11.4b)
Enterprise Value = 210b USD (207b + Debt 13.6b - CCE 11.4b)
Interest Coverage Ratio = 29.00 (Ebit TTM 9.40b / Interest Expense TTM 324.0m)
EV/FCF = 13.83x (Enterprise Value 210b / FCF TTM 15.2b)
FCF Yield = 7.23% (FCF TTM 15.2b / Enterprise Value 210b)
FCF Margin = 34.49% (FCF TTM 15.2b / Revenue TTM 43.9b)
Net Margin = 21.99% (Net Income TTM 9.66b / Revenue TTM 43.9b)
Gross Margin = 77.28% ((Revenue TTM 43.9b - Cost of Revenue TTM 9.98b) / Revenue TTM)
Gross Margin QoQ = 76.65% (prev 76.92%)
Tobins Q-Ratio = 1.91 (Enterprise Value 210b / Total Assets 110b)
Interest Expense / Debt = 2.39% (Interest Expense 324.0m / Debt 13.6b)
Taxrate = 5.63% (699.0m / 12.4b)
NOPAT = 8.87b (EBIT 9.40b * (1 - 5.63%))
Current Ratio = 0.84 (Total Current Assets 22.1b / Total Current Liabilities 26.3b)
Debt / Equity = 0.35 (Debt 13.6b / totalStockholderEquity, last quarter 38.4b)
Debt / EBITDA = 0.17 (Net Debt 2.17b / EBITDA 13.0b)
Debt / FCF = 0.14 (Net Debt 2.17b / FCF TTM 15.2b)
Total Stockholder Equity = 47.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.33% (Net Income 9.66b / Total Assets 110b)
RoE = 20.15% (Net Income TTM 9.66b / Total Stockholder Equity 47.9b)
RoCE = 16.10% (EBIT 9.40b / Capital Employed (Equity 47.9b + L.T.Debt 10.4b))
RoIC = 10.87% (NOPAT 8.87b / Invested Capital 81.6b)
WACC = 8.45% (E(207b)/V(221b) * Re(8.86%) + D(13.6b)/V(221b) * Rd(2.39%) * (1-Tc(0.06)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -81.96 | Cagr: -7.78%
[DCF] Terminal Value 77.63% ; FCFF base≈14.1b ; Y1≈16.2b ; Y5≈23.8b
[DCF] Fair Price = 424.2 (EV 351b - Net Debt 2.17b = Equity 349b / Shares 823.0m; r=8.45% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.66 | EPS CAGR: 25.95% | SUE: 4.0 | # QB: 5
Revenue Correlation: 99.73 | Revenue CAGR: 9.43% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-10-31): EPS=3.39 | Chg30d=+0.85% | Revisions=+25% | Analysts=22
EPS current Year (2027-01-31): EPS=14.67 | Chg30d=+3.80% | Revisions=+25% | GrowthEPS=+17.2% | GrowthRev=+11.2%
EPS next Year (2028-01-31): EPS=15.56 | Chg30d=+0.28% | Revisions=+12% | GrowthEPS=+6.0% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +30% (up=5, down=2)